Apex Biotechnology Corp Asset Resilience Ratio
Apex Biotechnology Corp asset resilience ratio. Apex Biotechnology Corp (1733) has an Asset Resilience Ratio of 3.32% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 1733 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Apex Biotechnology Corp (2002–2024)
Asset resilience ratio of Apex Biotechnology Corp from 2002 to 2024. This chart shows how Apex Biotechnology Corp's Asset Resilience Ratio has changed over time. Read 1733 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Apex Biotechnology Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Apex Biotechnology Corp's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$76.63 Million | 3.32% |
| Total Liquid Assets | NT$76.63 Million | 3.32% |
Asset Resilience Insights
- Limited Liquidity: Apex Biotechnology Corp maintains only 3.32% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Apex Biotechnology Corp Industry Peers by Asset Resilience Ratio
Compare Apex Biotechnology Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Apex Biotechnology Corp Asset Resilience Ratio by Year (2002–2024)
Apex Biotechnology Corp asset resilience ratio by year from 2002 to 2024. The table below shows the annual Asset Resilience Ratio data for Apex Biotechnology Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.73% | NT$66.10 Million ≈ $2.08 Million |
NT$2.42 Billion ≈ $76.24 Million |
+0.04pp |
| 2023-12-31 | 2.69% | NT$61.87 Million ≈ $1.95 Million |
NT$2.30 Billion ≈ $72.37 Million |
+0.08pp |
| 2022-12-31 | 2.62% | NT$65.83 Million ≈ $2.07 Million |
NT$2.51 Billion ≈ $79.23 Million |
-0.22pp |
| 2021-12-31 | 2.84% | NT$75.92 Million ≈ $2.39 Million |
NT$2.67 Billion ≈ $84.13 Million |
+1.48pp |
| 2020-12-31 | 1.36% | NT$36.01 Million ≈ $1.13 Million |
NT$2.65 Billion ≈ $83.53 Million |
-3.95pp |
| 2019-12-31 | 5.31% | NT$149.31 Million ≈ $4.70 Million |
NT$2.81 Billion ≈ $88.66 Million |
+2.01pp |
| 2018-12-31 | 3.29% | NT$83.78 Million ≈ $2.64 Million |
NT$2.55 Billion ≈ $80.20 Million |
+0.52pp |
| 2017-12-31 | 2.77% | NT$74.84 Million ≈ $2.36 Million |
NT$2.70 Billion ≈ $85.06 Million |
+1.48pp |
| 2016-12-31 | 1.29% | NT$32.37 Million ≈ $1.02 Million |
NT$2.50 Billion ≈ $78.79 Million |
-2.31pp |
| 2015-12-31 | 3.60% | NT$97.01 Million ≈ $3.06 Million |
NT$2.69 Billion ≈ $84.89 Million |
-2.58pp |
| 2014-12-31 | 6.18% | NT$163.51 Million ≈ $5.15 Million |
NT$2.64 Billion ≈ $83.33 Million |
-0.83pp |
| 2013-12-31 | 7.02% | NT$191.13 Million ≈ $6.02 Million |
NT$2.72 Billion ≈ $85.82 Million |
+5.26pp |
| 2012-12-31 | 1.76% | NT$48.38 Million ≈ $1.52 Million |
NT$2.75 Billion ≈ $86.58 Million |
-0.23pp |
| 2011-12-31 | 1.99% | NT$42.60 Million ≈ $1.34 Million |
NT$2.14 Billion ≈ $67.39 Million |
-0.01pp |
| 2010-12-31 | 2.00% | NT$38.99 Million ≈ $1.23 Million |
NT$1.95 Billion ≈ $61.45 Million |
-19.03pp |
| 2009-12-31 | 21.03% | NT$373.15 Million ≈ $11.76 Million |
NT$1.77 Billion ≈ $55.91 Million |
+19.69pp |
| 2008-12-31 | 1.34% | NT$19.88 Million ≈ $626.20K |
NT$1.49 Billion ≈ $46.80 Million |
-20.18pp |
| 2007-12-31 | 21.51% | NT$334.31 Million ≈ $10.53 Million |
NT$1.55 Billion ≈ $48.96 Million |
+17.55pp |
| 2005-12-31 | 3.97% | NT$44.45 Million ≈ $1.40 Million |
NT$1.12 Billion ≈ $35.30 Million |
-5.61pp |
| 2004-12-31 | 9.57% | NT$95.22 Million ≈ $3.00 Million |
NT$994.56 Million ≈ $31.33 Million |
-33.20pp |
| 2003-12-31 | 42.78% | NT$412.54 Million ≈ $13.00 Million |
NT$964.43 Million ≈ $30.38 Million |
+21.04pp |
| 2002-12-31 | 21.74% | NT$174.34 Million ≈ $5.49 Million |
NT$801.97 Million ≈ $25.27 Million |
-- |
About Apex Biotechnology Corp
Apex Biotechnology Corp. researches, develops, manufactures, and sells home care medical devices by using biosensor technology worldwide. The company offers blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1C, and ketone monitoring systems, as well as coagulation and multifunctional self-testing. It also provides pesticide residue check systems; and care management and tele-health s… Read more